Register | Login
Intellectual Property Today
RFC Express - Document Management System
2013 Top Patent Firms
2013 Top Trademark Firms
Current Issue

Advertising Opportunities

Click Here

Email A Friend Back to Archived News

Patent Awarded to Metabolon for Metabolomics Software

Tuesday, August 11, 2009

Ion Tracker™ Enables the Identification of Individual Biochemicals

Research Triangle Park, NC -- Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced that it has been awarded a patent for its metabolomics software, Ion Tracker™, which provides a mechanism for creating new chemical library entries. The software is designed to greatly accelerate and automate the organization of ion features for mass spectrometry into chemically related sets and expedites the creation of a metabolite library. It is a key component of the company’s global biochemical profiling technology.

Corey DeHaven, senior director of information systems with Metabolon, explained, "This tool gives us a unique advantage because we are able to dig very deeply into datasets and find those underlying chemicals that are not already a part of our library, then add them to the library with very little time or effort. It is in this way that Metabolon has been able to build the world’s largest metabolomic reference library and we continue to add to this database daily."

The awarded patent (US Patent 7,561,975), titled "System, Method, and Computer Program Product for Analyzing Spectrometry Data to Identify and Quantify Individual Component in a Sample," is the latest addition to Metabolon’s extensive IP portfolio consisting of over 100 US and worldwide patents and patent applications, including broad metabolomics methods, data analysis and biomarker patents, as well as focused product patents.

About Metabolon

Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit

Back to Archived News
Looking for...

  © Copyright 2013 Intellectual Property Today
Download Adobe Reader for free